Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Floxuridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TK1 | P04183 | 3/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | TK2 | O00142 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Floxuridine SCHEMBL18561102 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL6270910 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL9155703 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL13674187 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18573179 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL17229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL4939702 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11564431 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL11563300 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A | |
| Floxuridine SCHEMBL18597573 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2TK1ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540412-B2 | Methods of preparing targeted aptamer prodrugs | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-01-10 | — | — | US | claimed |
| WO-2011142798-A2 | METHODS OF PREPARING TARGETED APTAMER PRODRUGS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-11-17 | — | — | WO | claimed |
| US-12636304-B2 | — | — | 2026-05-26 | — | — | US | disclosed |
| US-20250186546-A1 | Compositions and Methods to Prevent, Inhibit or Treat Autoimmune and Vascular Disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-06-12 | — | — | US | disclosed |
| US-12263215-B2 | Cytotoxic immunostimulating particles and uses thereof | BioNTech SE (DE) | 2025-04-01 | — | — | US | disclosed |
| WO-2024233957-A2 | COMPOSITIONS AND METHODS TO PREVENT, INHIBIT OR TREAT NEURODEGENERATIVE DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240350621-A1 | DOUBLE STRANDED MRNA VACCINES | UNIV IOWA RES FOUND (US) | 2024-10-24 | — | — | US | disclosed |
| WO-2024112568-A1 | ANTISENSE OLIGOMER (ASO) AS AN INHIBITOR OF LIVER FIBROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-3365010-B1 | CYTOTOXIC IMMUNOSTIMULATING PARTICLES AND USES THEREOF | BioNTech SE (DE) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023144830-A1 | ZIKA M PROTEIN BLOCKERS AS ANTI-ZIKA VIRUS AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-08-03 | — | — | WO | disclosed |
| US-20230190769-A1 | E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2009-09-03 | — | — | US | disclosed |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2009-09-03 | — | — | US | disclosed |
| WO-2009042064-A2 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20080241068-A1 | SYSTEM AND METHODS FOR IDENTIFYING INDIVIDUALS AT RISK FOR SYSTEMIC FLUOROPYRIMIDINE TOXICITY | COHEN JAMES M | 2008-10-02 | — | — | US | disclosed |
| US-20070179112-A1 | POLYMERIC NUCLEOSIDE PRODRUGS | RELIABLE BIOPHARMACEUTICAL, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179112-A1 | POLYMERIC NUCLEOSIDE PRODRUGS | RELIABLE BIOPHARMACEUTICAL, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-7173020-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173020-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-4169201-A | Novel ester precursor intermediates and antipodes for the preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil | HOFFMANN-LA ROCHE INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636304-B2 | — | RNMT, RNGTT, NSUN2 | LMNA 1945/4885SMN1; SMN2 502/4885TK1 1815/4885 |
| US-20070179112-A1 | POLYMERIC NUCLEOSIDE PRODRUGS | TYMP, PNP, PAICS | LMNA 1505/4885SMN1; SMN2 1677/4885TK1 35/4885 |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | SAMHD1, TK2, DCTD | LMNA 1439/4885SMN1; SMN2 1103/4885TK1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.